Literature DB >> 17484992

Stem cell therapy improves myocardial perfusion and cardiac synchronicity: new application for echocardiography.

David Wolf1, Adrian Reinhard, Ulf Krause, Anja Seckinger, Hugo A Katus, Helmut Kuecherer, Alexander Hansen.   

Abstract

OBJECTIVES: Intravenous delivery of mesenchymal stem cell (MSC) is a noninvasive approach for myocardial tissue repair. We aimed to test this strategy in a pig model of myocardial infarction and to examine the usefulness of new echocardiographic applications to monitor cardioprotective effects of stem cell therapy.
METHODS: Pigs (n = 8) received autologous or allogeneic MSCs (1 x 10(6)/kg body weight) labeled with fluorescent dye 48 hours after proximal left anterior descending coronary artery occlusion. Infarct size, myocardial function, and perfusion (A x beta) were assessed by myocardial contrast echocardiography and standard histologic methods after 1 month.
RESULTS: Morphologic analysis revealed that labeled MSCs migrated in the peri-infarct region resulting in smaller infarct size by myocardial contrast echocardiography (control vs autologous and allogeneic MSC: 38 +/- 10% vs 25 +/- 5% and 28 +/- 6%, P < .01), higher fractional area shortening (23 +/- 3% vs 34.0 +/- 7% and 28 +/- 2%, P < .01), higher cardiac synchrony (167 +/- 36 vs 68 +/- 17 and 85 +/- 26 milliseconds, P < .003), and improved microvascular flow A x beta in the ischemic border zone (0.18 +/- 0.2 vs 0.56 +/- 0.3 and 0.49 +/- 0.2, P < .03).
CONCLUSIONS: Systemic delivery of autologous and allogeneic MSCs preserves myocardial viability even in large animals and is, therefore, an attractive approach for tissue repair. Myocardial contrast echocardiography is useful to evaluate microvascular perfusion, which was enhanced by MSCs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17484992     DOI: 10.1016/j.echo.2006.11.008

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  7 in total

1.  Echocardiographic evaluation of the effects of stem cell therapy on perfusion and function in ischemic cardiomyopathy.

Authors:  Yoichi Inaba; Brian P Davidson; Sajeevani Kim; Ya Ni Liu; William Packwood; J Todd Belcik; Aris Xie; Jonathan R Lindner
Journal:  J Am Soc Echocardiogr       Date:  2013-12-04       Impact factor: 5.251

Review 2.  Noninvasive cardiovascular imaging techniques for basic science research: application to cellular therapeutics.

Authors:  Wesley D Gilson; Dara L Kraitchman
Journal:  Rev Esp Cardiol       Date:  2009-08       Impact factor: 4.753

3.  Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6.

Authors:  Ryang Hwa Lee; Andrey A Pulin; Min Jeong Seo; Daniel J Kota; Joni Ylostalo; Benjamin L Larson; Laura Semprun-Prieto; Patrice Delafontaine; Darwin J Prockop
Journal:  Cell Stem Cell       Date:  2009-07-02       Impact factor: 24.633

4.  Intravenous mesenchymal stem cell therapy for traumatic brain injury.

Authors:  Matthew T Harting; Fernando Jimenez; Hasan Xue; Uwe M Fischer; James Baumgartner; Pramod K Dash; Charles S Cox
Journal:  J Neurosurg       Date:  2009-06       Impact factor: 5.115

5.  Culture and Use of Mesenchymal Stromal Cells in Phase I and II Clinical Trials.

Authors:  Bourin Philippe; Sensebé Luc; Planat-Bénard Valérie; Roncalli Jérôme; Bura-Rivière Alessandra; Casteilla Louis
Journal:  Stem Cells Int       Date:  2010-10-31       Impact factor: 5.443

6.  Multimodality molecular imaging to monitor transplanted stem cells for the treatment of ischemic heart disease.

Authors:  Zhijun Pei; Xiaoli Lan; Zhen Cheng; Chunxia Qin; Xiaotian Xia; Hui Yuan; Zhiling Ding; Yongxue Zhang
Journal:  PLoS One       Date:  2014-03-07       Impact factor: 3.240

Review 7.  Genetically‑modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1)‑based targeted therapy (Review).

Authors:  Marina Devetzi; Maria Goulielmaki; Nicolas Khoury; Demetrios A Spandidos; Georgia Sotiropoulou; Ioannis Christodoulou; Vassilis Zoumpourlis
Journal:  Int J Mol Med       Date:  2018-01-03       Impact factor: 4.101

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.